Filing Flows › Consumer Staples › Endovia Health Sciences (EDVA)
Endovia Health Sciences (EDVA) earnings and revenue breakdown
Latest: Q1 2026 · 10-Q filed May 20, 2026 · Endovia Health Sciences (EDVA) Q1 2026 earnings results →
Q1 2026 Revenue down 94% year over year to $4K
Endovia Health Sciences made $4K in Q1 2026 (-94% Y/Y). Operating margin n/m, net earnings $2.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed May 20, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $4K in Q1 2026, down 94% year over year.
Gross margin was 43.8%, up 6.5 points from Q1 2025. Operating costs exceeded revenue by $1.0M, an operating margin of -23176.4%. Operating expenses fell 42% while revenue fell 94%. Net earnings were −$2.1M. The effective tax rate was 0.0%. Non-operating items added $3.5M, 139% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$930K. Non-cash charges added back $2K of depreciation and $177K of share-based compensation. Working capital and other items used $3.6M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q1 2026 | 10-Q | May 20, 2026 | $4K | -94% | n/m | $2.5M | −$930K |
| Q1 2025 | 10-Q | Jul 11, 2025 | $438K | -72% | -463.8% | −$3.7M | −$724K |
| Q4 2024 | 10-K | Jul 11, 2025 | $586K | -78% | n/m | −$9.0M | −$1.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Endovia Health Sciences
Historically, Splash was a portfolio company seeking to manage brands across viable growth segments within the consumer beverage industry. As a result of our lack of capital, we did not generate revenue from February 2025 until March 2026 when we delivered tequila as described below. Our beverage operations have historically not been profitable. Because of our lack of capital to generate revenue, our management reviewed strategic alternatives inside and outside of the beverage industry. As a result, on March 4, 2026 the Company entered into a non-binding letter of intent setting forth the principal terms of a potential acquisition of a leading manufacturer and multi-brand operator of federally compliant cannabinoid wellness products. See “Letter of Intent” immediately below for more information.
In its own words, from its 10-K, filed Apr 15, 2026.
Endovia Health Sciences against its Beverages peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -94% against the peers' median +6%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| EDVA Endovia Health Sciences | Q1 2026 | $4K | -94% | n/m |
| PEP PepsiCo | Q3 2026 | $25.3B | +6% | 16.9% |
| KO Coca Cola | Q3 2026 | $13.4B | +7% | 33.4% |
| KDP Keurig Dr Pepper | Q3 2026 | $7.3B | +71% | 18.2% |
| STZ Constellation Brands | Q2 FY27 | $2.8B | +6% | 28.6% |
| PRMB Primo Brands | Q3 2026 | $1.8B | +3% | 13.7% |
| BF-B Brown Forman | Q1 FY27 | $1.2B | -0.8% | 21.3% |
| WEST Westrock Coffee | Q3 2026 | $300M | -15% | 1.1% |
| COCO Vita Coco Company | Q3 2026 | $244M | +34% | 18.6% |
Source: Endovia Health Sciences 10-Q on SEC EDGAR · CIK 1553788 · Beverages
More on EDVA
History
Every quarter: Q1 2026 results · Q1 2025 results · Q4 2024 results